Akums Drugs and Pharmaceutical (AKUMS) - Total Liabilities

Latest as of September 2025: Rs19.91 Billion INR ≈ $215.30 Million USD

Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) has total liabilities worth Rs19.91 Billion INR (≈ $215.30 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AKUMS cash flow metrics to assess how effectively this company generates cash.

Akums Drugs and Pharmaceutical - Total Liabilities Trend (2022–2025)

This chart illustrates how Akums Drugs and Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Check AKUMS asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Akums Drugs and Pharmaceutical Competitors by Total Liabilities

The table below lists competitors of Akums Drugs and Pharmaceutical ranked by their total liabilities.

Company Country Total Liabilities
Metalurgica Gerdau S.A
SA:GOAU3
Brazil R$32.53 Billion
Sipef NV
BR:SIP
Belgium €167.17 Million
I.E.S Holdings Ltd
TA:IES
Israel ILA332.15 Million
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
USA $45.74 Million
Zhejiang Zhongxin Fluoride Materials Co Ltd Class A
SHE:002915
China CN¥1.89 Billion
MAHLE Metal Leve S.A
SA:LEVE3
Brazil R$3.09 Billion
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
China CN¥3.11 Billion
Eckert & Ziegler Strahlen- und Medizintechnik AG
F:EUZ
Germany €204.50 Million

Liability Composition Analysis (2022–2025)

This chart breaks down Akums Drugs and Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Akums Drugs and Pharmaceutical (AKUMS) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.63 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.39 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Akums Drugs and Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Akums Drugs and Pharmaceutical (2022–2025)

The table below shows the annual total liabilities of Akums Drugs and Pharmaceutical from 2022 to 2025.

Year Total Liabilities Change
2025-03-31 Rs10.50 Billion
≈ $113.54 Million
-62.45%
2024-03-31 Rs27.96 Billion
≈ $302.36 Million
+9.94%
2023-03-31 Rs25.43 Billion
≈ $275.03 Million
+4.06%
2022-03-31 Rs24.44 Billion
≈ $264.30 Million
--

About Akums Drugs and Pharmaceutical

NSE:AKUMS India Drug Manufacturers - Specialty & Generic
Market Cap
$906.19 Million
Rs83.79 Billion INR
Market Cap Rank
#9553 Global
#449 in India
Share Price
Rs547.30
Change (1 day)
+0.66%
52-Week Range
Rs414.05 - Rs594.00
All Time High
Rs1119.95
About

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and co… Read more